Diet and uptake of aldomet by the brain: competition with natural large neutral amino acids.

The rise in levels of aldomet in the brains of rats after an injection of the alpha-methylated amino acid was depressed when large neutral amino acids, but not acidic amino acids, were coadministered with the drug. This result suggests that aldomet is transported into brain by the carrier for natural large neutral amino acids. The prior ingestion of a carbohydrate meal, which lowers levels of neural amino acids in the serum, enhanced the uptake of aldomet into brain; the consumption of a protein-containing meal inhibited the subsequent uptake of aldomet into the brain. Antecedent diet can thus affect the availability of aldomet to the central nervous system; the mechanism of this effect probably involves the blood-brain barrier uptake system for large neutral amino acids.

Brain serotonin content: physiological dependence on plasma tryptophan levels.

Brain serotonin cocentrations at 1 p.m. were significantly elevated 1 hour after rats received a dose of L-tryptophan (12.5 milligrams per kilogram. intraperitoneally) smaller than one-twentieth of the normal daily dietary intake. Plasma and brain tryptophan levels were elevated 10 to 60 minutes after the injection, but they never exceeded the concentrationis that occur nocturnally in untreated aninmals as result of their normal 24-hour rhythms. These data suggest that physiological changes in plasma tryptophan concentration influenice brain serotonin levels.

Brain serotonin content: increase following ingestion of carbohydrate diet.

In the rat, the injection of insulin or the consumption of carbohydrate causes sequential increases in the concentrations of tryptophan in the plasma and the brain and of serotonin in the brain. Serotonin-containing neurons may thus participate in systems whereby the rat brain integrates information about the metabolic state in its relation to control of homeostatis and behavior.

Brain serotonin content: physiological regulation by plasma neutral amino acids.

When plasma tryptophan is elevated by the injection of tryptophan or insulin, or by the consumption of carbohydrates, brain tryptophan and serotonin also rise; however, when even larger elevations of plasma tryptophan are produced by the ingestion of protein-containing diets, brain tryptophan and serotonin do not change. The main determinant of brain tryptophan and serotonin concentrations does not appear to be plasma tryptophan alone, but the ratio of this amino acid to other plasma neutral amino acids (that is, tyrosine, phenylalanine, leucine, isoleucine, and valine) that compete with it for uptake into the brain.

Brain catechol synthesis: control by train tyrosine concentration.

Brain catechol synthesis was estimated by measuring the rate at which brain dopa levels rose following decarboxylase inhibition. Dopa accumulation was accelerated by tyrosine administration, and decreased by treatments that lowered brain tyrosine concentrations (for example, intraperitoneal tryptophan, leucine, or parachlorophenylalanine). A low dose of phenylalanine elevated brain tyrosine without accelerating dopa synthesis. Our findings raise the possibility that nutritional and endocrine factors might influence brain catecholamine synthesis by controlling the availability of tyrosine.

A defect in sodium-dependent amino acid uptake in diabetic rabbit peripheral nerve. Correction by an aldose reductase inhibitor or myo-inositol administration.

A myo-inositol-related defect in nerve sodium-potassium ATPase activity in experimental diabetes has been suggested as a possible pathogenetic factor in diabetic neuropathy. Because the sodium-potassium ATPase is essential for other sodium-cotransport systems, and because myo-inositol-derived phosphoinositide metabolites regulate multiple membrane transport processes, sodium gradient-dependent amino acid uptake was examined in vitro in endoneurial preparations derived from nondiabetic and 14-d alloxan diabetic rabbits. Untreated alloxan diabetes reduced endoneurial sodium-gradient dependent uptake of the nonmetabolized amino acid 2-aminoisobutyric acid by greater than 50%. Administration of an aldose reductase inhibitor prevented reductions in both nerve myo-inositol content and endoneurial sodium-dependent 2-aminoisobutyric acid uptake. Myo-inositol supplementation that produced a transient pharmacological elevation in plasma myo-inositol concentration, but did not raise nerve myo-inositol content, reproduced the effect of the aldose reductase inhibitor on endoneurial sodium-dependent 2-aminoisobutyric acid uptake. Phorbol myristate acetate, which acutely normalizes sodium-potassium ATPase activity in diabetic nerve, did not acutely correct 2-aminoisobutyric uptake when added in vitro. These data suggest that depletion of a small myo-inositol pool may be implicated in the pathogenesis of defects in amino acid uptake in diabetic nerve and that rapid correction of sodium-potassium ATPase activity with protein kinase C agonists in vitro does not acutely normalize sodium-dependent 2-aminoisobutyric acid uptake.

Consensus meeting: monosodium glutamate - an update.

OBJECTIVE: Update of the Hohenheim consensus on monosodium glutamate from 1997: Summary and evaluation of recent knowledge with respect to physiology and safety of monosodium glutamate. DESIGN: Experts from a range of relevant disciplines received and considered a series of questions related to aspects of the topic. SETTING: University of Hohenheim, Stuttgart, Germany. METHOD: The experts met and discussed the questions and arrived at a consensus. CONCLUSION: Total intake of glutamate from food in European countries is generally stable and ranged from 5 to 12 g/day (free: ca. 1 g, protein-bound: ca. 10 g, added as flavor: ca. 0.4 g). L-Glutamate (GLU) from all sources is mainly used as energy fuel in enterocytes. A maximum intake of 6.000 [corrected] mg/kg body weight is regarded as safe. The general use of glutamate salts (monosodium-L-glutamate and others) as food additive can, thus, be regarded as harmless for the whole population. Even in unphysiologically high doses GLU will not trespass into fetal circulation. Further research work should, however, be done concerning the effects of high doses of a bolus supply at presence of an impaired blood brain barrier function. In situations with decreased appetite (e.g., elderly persons) palatability can be improved by low dose use of monosodium-L-glutamate.

Effect of experimental diabetes on the levels of aromatic and branched-chain amino acids in rat blood and brain.

Male rats treated 3 wk earlier with streptozotocin showed abnormally high blood levels of leucine, isoleucine, and valine throughout the 24-h period. Serum phenylalanine levels were slightly increased, while those of tryptophan and tyrosine were occasionally reduced. In brain, the level of each branched-chain amino acid was significantly increased above normal at all times. The brain concentration of each aromatic amino acid was always below normal. These changes were restored almost to normal by exogenous insulin therapy. Since the ingestion of protein is normally a major factor influencing blood amino acid levels, the effect of ingesting single, protein-containing meals on the blood and brain levels of these amino acids was also studied. After an overnight fast, the ingestion of a protein-containing meal by diabetic rats increased substantially both blood and brain levels of each branched-chain amino acid. No such increases occurred in normal rats. Ingestion of this meal produced only small changes in the brain and blood levels of the aromatic amino acids in both diabetic and normal rats. The changes in the brain level of each large neutral amino acid in some cases paralleled those in its blood level. More often, they paralleled the changes in the blood ratio of each amino acid to the sum of the other aromatic and branched-chain amino acids. This ratio is often a good predictor of the competitive transport of these amino acids into brain (Fernstrom and Faller, 1978). The observed changes in the brain levels of these amino acids in diabetes may influence the rates at which they are consumed in metabolic pathways within this organ.

Effects of precursors on brain neurotransmitter synthesis and brain functions.

This paper reviews factors which influence the levels of aminergic transmitters in the brain. In particular precursor availability to the brain influences the rates of synthesis of serotonin, the catecholamines, and acetylcholine by brain neurons. The diet readily influences brain neurotransmitter formation via this mechanism. At present, the importance of this relationship to body regulation is not well understood. Nonetheless, precursors (tryptophan, tyrosine, choline, and lecithin) have begun to find uses as therapeutic agents in the treatment of disease states involving diminished transmitter formation and release. Hopefully, these compounds will find a wide range of uses, as they lack many of the side effects that accompany the use of drugs.

In vivo biosynthesis of arginine vasopressin and oxytocin in hypothalami from intact and hypophysectomized rats.

The rates of incorporation of [35S]cysteine into arginine vasopressin (AVP) and oxytocin (OXT) were studied concurrently in hypothalami from intact and hypophysectomized male rats. After label injection into the third ventricle, rats were killed 0.5, 1, 2, 4, or 8 h later. The hypothalamic peptides were quantitated by specific RIA and separated by HPLC to allow quantitation of label incorporation into each peptide. In intact rats, labeling of both OXT and AVP rose rapidly to peak at 2 h; thereafter, radioactivity in both peptides declined slowly to 8 h. In hypophysectomized rats, labeling of AVP fell below that in intact animals at all time points. Labeling of OXT was somewhat below normal 2 h after label injection, but considerably above normal at 4 and 8 h. For comparison, label incorporation into somatostatin-14 (SRIF-14) and somatostatin-28 (SRIF-28) was also studied in the same animals. In intact rats, labeling of both SRIF peptides rose slowly to maximal values at 8 h. In hypophysectomized animals, labeling of each peptide was reduced substantially at all times tested. Endogenous cysteine specific activity and protein specific activity did not differ between intact and hypophysectomized animals. Immunoreactive levels of AVP and OXT in the hypothalamus were unaffected by hypophysectomy, though total SRIF-like immunoreactivity was depressed. Together these results suggest that hypothalamic neurons synthesize OXT and AVP at rates much faster than those for the SRIF peptides, and that hypophysectomy has differential effects on the syntheses of cysteine-containing peptides in the hypothalamus. Specifically, the syntheses of SRIF-14 and SRIF-28 appear to be sizeably reduced in hypophysectomized rats, while that of AVP only modestly diminished. OXT synthesis may be increased.

Serotonin receptor antagonists block a natural, short term surge in serum growth hormone levels.

Serum GH levels in untreated rats were found to increase spontaneously to over 300 ng/ml around the onset of darkness (1900 h) and then decrease to under 100 ng/ml by 2000 h. Pretreatment with the serotonin receptor blockers, metergoline (0.2, 0.5, 1, or 2 mg/kg) or cyproheptadine (1, 2, or 5 mg/kg), at 1800 h significantly blunted this physiological rise in serum GH. In rats bearing chronic right atrial cannulae from which blood samples were drawn every 15 min for 5 h, the administration of metergoline (1 mg/kg) was also observed to reduce plasma GH levels over a 3.25-h period. Serotonin-containing neurons in the brain thus seem to be involved in the physiological secretion of GH.

L-Tryptophan injection enhances pulsatile growth hormone secretion in the rat.

The effect of injecting L-tryptophan or a serotonin receptor agonist [6-Cl-2-[1-piperazinyl]pyrazine ((MK0212)] on pulsatile GH secretion was studied in male rats bearing right atrial cannulae. After injection, blood samples were drawn at 15-min intervals for periods up to 4 h. L-Tryptophan administration (50 or 100 mg/kg, ip) significantly enhanced mean plasma GH levels measured over a 3.5-h period. Injection of another large neutral amino acid, L-valine (100 mg/kg, ip), did not influence plasma GH levels. However, when administered with tryptophan, valine blocked the tryptophan-induced enhancement of GH secretion and blunted the increases in brain tryptophan and serotonin levels that normally accompany tryptophan injection. Injection of MK-212 (2 mg/kg, ip) elicited an immediate rise in plasma GH levels; this effect was completely blocked by pretreatment with metergoline (2 mg/kg, ip), a serotonin receptor antagonist. Taken together, these data support the notion that treatments which increase serotonin receptor stimulation enhance or induce pulsatile GH secretion.

L-Dopa inhibits prolactin secretion in proestrous rats.

Female rats received an ip injection of L-dopa on the afternoon of proestrus. L-Dopa reduced serum prolactin concentrations within 1 h, whether administered just prior to, or during, the normal surge in serum hormone level. This inhibition lasted for 2-3 h, after which serum prolactin concentrations rose substantially. Pretreatment of proestrous rats with MK-486, a peripheral inhibitor of aromatic-L-amino acid decarboxylase, did not block the effect of L-dopa on serum prolactin levels. In fact, MK-486 pretreatment appeared to prolong the effectiveness of L-dopa. Pretreatment with RO4-4602 at a dose sufficient to block central decarboxylase activity, however, did prevent dopa from inhibiting the proestrous surge in serum prolactin. These data are consistent with a role for dopamine in the control of prolactin secretion and suggest that the mechanism of action of L-dopa apparently does not require peripheral decarboxylation.

Effects of cysteamine administration on the in vivo incorporation of [35S]cysteine into somatostatin-14, somatostatin-28, arginine vasopressin, and oxytocin in rat hypothalamus.

The effect of cysteamine injection on the in vivo incorporation of [35S]cysteine into somatostatin-14 (SRIF-14), SRIF-28, arginine vasopressin (AVP), and oxytocin (OXT) in rat hypothalamus was studied. [35S]Cysteine was injected into the third ventricle 1 h, 4 h, or 1 week after cysteamine (300 mg/kg, sc) injection; animals were killed 4 h later. The drug was found to substantially reduce immunoreactive SRIF levels, but not OXT or AVP, 4 h after its injection. Cysteamine also caused large reductions in label incorporation into SRIF-14, SRIF-28, and OXT 1 and 4 h after drug injection. However, [35S]cysteine incorporation into AVP was increased substantially at these time points, while that into acid-precipitable protein was normal. One week after cysteamine injection, label incorporation into all hypothalamic peptides was normal. Cysteine specific activity was also measured after [35S]cysteine injection and was found to be similar in treatment and control groups. The results suggest that cysteamine inhibits the syntheses of SRIF-14, SRIF-28, and OXT and stimulates that of AVP.

In vivo biosynthesis of L-[35S]Cys-arginine vasopressin, -oxytocin, and -somatostatin: rapid estimation using reversed phase high pressure liquid chromatography.

L[35S]Cys-arginine vasopressin, -oxytocin, and -somatostatin were purified from hypothalami and neurohypophyses 4 h after rats received L[35S]Cys via the third ventricle. After acetic acid extraction, Sephadex G-25 filtration, and chemoadsorption to C18-silica (Sep-Pak cartridges), the labeled peptides were rapidly separated by gradient elution, reversed phase, high pressure liquid chromatography (HPLC). The identity and isotopic purity of the labeled peptides were determined by several reversed phase HPLC procedures in conjunction with chemical modification. The labeled peptide fractions were at least 50% radiochemically pure. Using this HPLC isolation procedure, incorporation of L-[35S]Cys into each peptide was determined n hydrated and dehydrated rats. Label incorporation into arginine vasopressin and oxytocin in the hypothalamus and the neurohypophysis of dehydrated rats was 2-3 times greater than that in hydrated rats. Incorporation of label into hypothalamic and neurohypophyseal somatostatin was unaffected by the hydration state of the animal. This procedure thus provides a very rapid, but sensitive, set of techniques for studying the control of small peptide biosynthesis in the brain.

In vivo studies of somatostatin-14 and somatostatin-28 biosynthesis in rat hypothalamus.

The biosynthesis of somatostatin-14 (SRIF-14) and somatostatin-28 (SRIF-28) was studied in rat hypothalamus after injection of 35S-labeled cysteine into the third ventricle. Cysteine specific activity was quantitated, and found to decline rapidly after injection of the labeled amino acid: less than 0.1% of the injected label remained as free cysteine in the hypothalamus 30 min post injection. Incorporation of label into SRIF-14 and SRIF-28 reached maximum values 8 h post injection, compared with a labeling maximum at 1-2 h for acid-precipitable protein. Within 2 h after [35S]cysteine injection, nearly half of the total labeled hypothalamic SRIF appeared in the medial basal hypothalamus; 24-h post injection this percentage reached approximately 75%. Colchicine administration dramatically reduced the appearance of labeled SRIF in medial basal hypothalamus, but had no apparent effect on the total incorporation of [35S]cysteine into SRIF-14, SRIF-28, or acid-precipitable protein, or on radioimmunoassayable SRIF levels. These results suggest that 1) the technique employed for administering [35S] cysteine delivers the label as a pulse; 2) the timing of the appearance of labeled amino acid in SRIF-14, SRIF-28, and acid-precipitable protein is consistent with initial synthesis of a larger prohormone, followed by conversion to peptide products; and 3) the newly synthesized peptides are rapidly transported to the medial basal hypothalamus by a colchicine sensitive mechanism.

Acute, oral ethanol administration suppresses episodic growth hormone secretion in the male rat.

The effect of single dose ethanol administration on GH secretion was studied in young adult male rats bearing indwelling gastric and right-atrial cannulas. Rats (nonfasted) received saline or ethanol (1, 2, 3, or 4 g/kg) via gastric cannula 2h before the onset of the daily dark period; blood was sampled every 15 min for 5 h. Each rat served as its own control, receiving saline and one ethanol dose separated by 2-3 days. Plasma samples were assayed for ethanol, GH, and testosterone. On saline days, all rats showed typical, episodic peaks of GH in plasma. This pattern was unaffected by ethanol at 1 g/kg (peak plasma ethanol approximately 65 mg/100 ml). Ethanol at 2 g/kg caused a rapid, marked, but not total suppression of plasma GH levels (peak plasma ethanol approximately 140 mg/100 ml), whereas at doses of 3 or 4 g/kg ethanol, a total suppression of GH secretion occurred (peak plasma ethanol approximately 190 and 240 mg/100 ml, respectively). Plasma testosterone levels showed a similar dose-sensitivity to ethanol. The threshold for GH suppression appears to be around 100 mg/100 ml plasma ethanol and is sustained throughout the time period examined, despite falling ethanol levels.

Reduction in brain serotonin synthesis rate in streptozotocin-diabetic rats.

The rate of serotonin synthesis in brain was determined in streptozotocin-diabetic and normal rats using two methods. Both the rate of 5-hydroxytryptophan accumulation after aromatic amino acid decarboxylase inhibition, and the decline rate of 5-hydroxyindole acetic acid after pargyline treatment were significantly reduced in diabetic rats. The reduced rate of synthesis may be a direct result of significantly lowered brain tryptophan levels in diabetic rats.

Effects of cysteamine administration on somatostatin biosynthesis and levels in rat hypothalamus.

A single injection of cysteamine (CSH; 2-aminoethanethiol; 300 mg/kg, sc) into male rats produced a rapid decline in immunoreactive somatostatin (IR-SRIF) levels in the hypothalamus (to 20% of preinjection values within 12 h) which persisted for several days. The levels of both somatostatin-14 (SRIF-14) and somatostatin-28 (SRIF-28) were reduced. In contrast, the levels of somatostatin-28(1-12) were unaffected. Most (80-90%) of the lost SRIF molecules (both SRIF-14 and SRIF-28) could be recovered from CSH-injected rats by subjecting hypothalamic samples to denaturing, reducing, and reoxidizing conditions. These results suggest that CSH does not deplete the hypothalamus of SRIF molecules, but, instead, alters their chemical structures, rendering them undetectable using a SRIF-14-directed RIA. CSH injection also caused a rapid and complete suppression (within 1 h) of [35S]cysteine incorporation into SRIF-14 and SRIF-28. This reduction, however, was short-lived; normal incorporation rates returned within 10 h of drug administration. CSH did not influence [35S] cysteine incorporation into acid-precipitable protein or [35S]cysteine specific activity in the hypothalamus. In addition, [35S]SRIF molecules were not recovered from hypothalami of CSH-treated rats by subjecting samples to denaturing, reducing, and then reoxidizing conditions. These findings indicate that CSH injection causes a true, but short-lived (1- to 10-h), suppression of hypothalamic SRIF-14 and SRIF-28 formation. Finally, biosynthesis studies of longer duration revealed no prolonged effects of CSH. The drug produced no changes 4, 24, or 72 h postinjection in hypothalamic levels of the prepro-SRIF mRNA. Moreover, two injections of CSH, separated by 3 days, which continuously suppressed IR-SRIF levels for almost 1 week, caused only a transient suppression of [35S]SRIF-14 and [35S]SRIF-28 synthesis after each injection. These results indicate that the SRIF biosynthetic pathway is not activated by the prolonged CSH-induced depletion of IR-SRIF stores.

Radioimmunologic detection and measurement of nonapeptides in the pineal gland.

RIAs have been developed for the nonapeptide hormones arginine vasotocin (AVT), arginine vasopressin (AVP), and oxytocin (OT). The AVP RIA can detect as little as 2 pg hormone and shows essentially no cross-reactivity with AVT or OT. The OT RIA is sensitive to 7 pg and shows no significant cross-reactivity with AVP or AVT. The AVT RIA is sensitive to about 5 pg; some cross-reactivity occurs with OT and AVP, but the RIA is suitable for assaying AVT levels in biological samples containing OT and/or AVP in concentrations up to 5 times greater than that of AVT. Using these RIAs, we found large amounts of AVT (up to 1.48 microgram/gland) in the chicken pituitary but no AVP or OT. The chicken pineal also contained AVT (about 300 pg/gland) and lacked AVP and OT. Bovine pineal glands appeared to contain all three peptides in roughly similar amounts (200-400 pg/gland). Pineal glands from a variety of rodents (including the rat) contained only very small amounts of AVT-like immunoreactivity (about 10 pg/gland) and no AVP or OT. Because AVT immunoreactivity appears in the pineals of several species, the peptide may subserve some physiological function of this organ. The functional roles, if any, of AVP and OT in the bovine pineal are unknown.